These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


204 related items for PubMed ID: 6346238

  • 1. [Primary hyperlipoproteinemias. Clinical, biological and physiopathological aspects].
    Bakir R, Chanu B, Rouffy J.
    Pathol Biol (Paris); 1983 Apr; 31(4):248-58. PubMed ID: 6346238
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical features of lipoprotein disorders.
    Lloyd JK.
    Ric Clin Lab; 1982 Apr; 12(1):97-100. PubMed ID: 7089428
    [No Abstract] [Full Text] [Related]

  • 5. [Primary hyperlipoproteinemias--pathophysiology, clinical aspects and genetics].
    Keller C, Zöllner N.
    Internist (Berl); 1992 Jan; 33(1):9-15. PubMed ID: 1551767
    [No Abstract] [Full Text] [Related]

  • 6. [Hypertriglyceridemias].
    Delgado M, Torres MA, Bellod P, Rubio MJ, Azpeitia JG, Nuño J, de Oya M.
    Rev Clin Esp; 1985 Oct; 177(5):203-8. PubMed ID: 3909257
    [No Abstract] [Full Text] [Related]

  • 7. Genetic hyperlipidemia and atherosclerosis.
    Stone NJ.
    Artery; 1979 May; 5(5):377-97. PubMed ID: 262162
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V, Klör HU, Wechsler JG, Ditschuneit H.
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [Abstract] [Full Text] [Related]

  • 12. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 13. Pathogenesis and management of lipoprotein disorders.
    Schaefer EJ, Levy RI.
    N Engl J Med; 1985 May 16; 312(20):1300-10. PubMed ID: 3887163
    [No Abstract] [Full Text] [Related]

  • 14. [Primary hyperlipoproteinemia from its clinical and laboratory aspects. V. Evaluation of circulatory hemodynamics based on the measurements of systolic time intervals and the physical analysis of blood circulation].
    Olejak B, Szmatłoch E, Brzeźniak R, Gregorczyk J, Pieczul-Mróz J, Jankowska E, Jagła A.
    Przegl Lek; 1983 May 16; 40(11):797-801. PubMed ID: 6669732
    [No Abstract] [Full Text] [Related]

  • 15. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G, Kłosiewicz-Latoszek L.
    Wiad Lek; 1985 Aug 15; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H, Bojanovski D.
    Artery; 1980 Aug 15; 8(2):171-8. PubMed ID: 7458684
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.